Name: Recombinant Anti-Ang2 x Anti-VEGFA Bispecific Antibody (scFv-Fc-scFv)
SKU: BSTF-008
Rating: 5 (1 reviews)

Recombinant Anti-Ang2 x Anti-VEGFA Bispecific Antibody (scFv-Fc-scFv) is designed to be expressed as one chain, then assembled to a homodimer of bivalent scFv fragments and the Fc region of IgG. The anti-Ang2 scFv is fused to the N-terminus of Fc via a hinge region while another anti-VEGFA scFv is linked to the C-terminus of Fc. This scFv-Fc-scFv format has 2+2 antigen-binding valency by employing different scFv fragments. This BsAb is capable of inhibiting two proangiogenics fators and a combined blockade of them has a greater inhibitory efficacy compared with inhibition of either factor alone. It is designed for the research of Colorectal cancer (CRC); Solid tumors; Wet AMD (Age-related macular degeneration); Diabetic macular edema therapy.

Datasheet INQUIRY

Specifications

Targets

Ang2 & VEGFA

Type

scFv-Fc-scFv

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Colorectal cancer (CRC); Solid tumors; Wet AMD (Age-related macular degeneration); Diabetic macular edema

Host Animal 1

Mouse

Host Animal 2

Mouse

Targets

Target 1

Ang2

Gene ID

285

UniProt ID

O15123

Alternative Names

ANGPT2; Ang2; angiopoietin 2; ANG2; AGPT2; angiopoietin-2; ANG-2; Tie2-ligand; angiopoietin-2B; angiopoietin-2a

Target 2

VEGFA

Gene ID

7422

UniProt ID

P15692

Alternative Names

VEGFA; vascular endothelial growth factor A; VPF; VEGF; MVCD1; vascular permeability factor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-Ang2 x Anti-VEGFA Bispecific Antibody (scFv-Fc-scFv) (BSTF-008). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-Ang2 x Anti-VEGFA Bispecific Antibody (scFv-Fc-scFv) (CAT#: BSTF-008)

Specifications

Targets

Customer Reviews and Q&As